Drug Profile
Liquid fibrin sealant - OMRIX Biopharmaceuticals
Alternative Names: Evicel; QuixilLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Developer Ethicon; OMRIX Biopharmaceuticals
- Class Acute-phase proteins; Adhesives; Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
- Mechanism of Action Fibrinogen replacements; Thrombin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Surgical blood loss
Most Recent Events
- 07 Sep 2021 Discontinued - Phase-II for Surgical blood loss in South Korea (Topical) (OMRIX Biopharmaceuticals website, September 2021)
- 13 Sep 2017 No recent reports on development identified - Phase-II for Surgical blood loss in South Korea (Topical)
- 27 May 2015 Ethicon plans a phase III trial for Surgical blood loss in USA, Australia, Belgium, Germany and United Kingdom (NCT02457546)